Why Stoke Therapeutics’ Dravet syndrome drug is worth watching
Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial for its experimental drug for Dravet syndrome.
Related Articles
Artificial intelligence improves mammography-based breast cancer risk prediction
Artificial intelligence (AI) is enabling us to delve deeply into the information inherent in a mammogram and identify novel features associated with high risk of…
Thursday, December 12, 2024 – KFF Health News
Nicotine limits, bird flu vaccine, latest on UnitedHealthcare exec murder, Tricare, legal issues facing insurers, ADHD diagnoses, and more.
Method of the Year 2024: spatial proteomics
Nature Methods – Approaches for profiling the spatial proteome in tissues are the basis of atlas-scale projects that are delivering on their promise for understanding…
Hyro AI raises $35M series B with Healthier Capital’s Amir Rubin
Hyro AI has brought in $35 million in an extension of its series B round, recently securing an investment from Healthier Capital, led by former…
Accuhealth, Signallamp rebrands as TelliHealth, appoints CEO
The chronic care management and remote patient monitoring company will be led by veteran healthcare executive Asif Ahmad.
The benefits of Ozempic and its kin may extend far beyond weight loss
Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight…
Looking Ahead to 2025: A Year of Innovation and Connection
As a seasoned B2B tech influencer and industry expert, I know the power of storytelling in shaping perceptions, driving engagement, and building meaningful connections. This…
Redesign Health raises $175M after layoffs
Redesign’s new fund announcement follows a series of layoffs and strategic shifts for the company.
Serious Liver Injury Being Observed in Patients Without Cirrhosis
Monitor Liver Tests Often for Early Identification of Worsening Liver Function
Health insurer Centene forecasts upbeat 2025 profit amid cost pressures
U.S. health insurer Centene on Thursday projected 2025 profit above Wall Street expectations amid elevated costs in its government-backed plans and a public outcry over…
